The BioMedWire Podcast

podcast@investorbrandnetwork.com
  • 0.0 (0)
  • Business News
  • Updated Daily

Fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation

  1. Jun 26

    Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

    BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (Profile) is challenging that reality. The company is advancing Lucid-MS, a patented, first-in-class drug candidate that takes a fundamentally different approach by directly targeting the myelin sheath that MS destroys, and this new drug candidate is preparing to enter phase 2 clinical trials. Quantum BioPharma is one of several companies focused on the development and commercialization of therapies for neurological, autoimmune and immune-mediated diseases, including Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and Clene Inc. (NASDAQ: CLNN). What makes MS particularly devastating is its progressive nature. Rather than targeting the immune system, Quantum BioPharma’s Lucid-MS targets the myelin sheath. The case for Lucid-MS is grounded in more than a decade of rigorous science. Quantum BioPharma’s path to phase 2 has been methodical and deliberate. To read the Full Publication, visit https://ibn.fm/wILk2 For further information about Quantum BioPharma Ltd., visit the Quantum BioPharma profile. To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com

    21 min

  2. Jun 26 ·  Video

    Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis [Video Edition]

    BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (Profile) is challenging that reality. The company is advancing Lucid-MS, a patented, first-in-class drug candidate that takes a fundamentally different approach by directly targeting the myelin sheath that MS destroys, and this new drug candidate is preparing to enter phase 2 clinical trials. Quantum BioPharma is one of several companies focused on the development and commercialization of therapies for neurological, autoimmune and immune-mediated diseases, including Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and Clene Inc. (NASDAQ: CLNN). What makes MS particularly devastating is its progressive nature. Rather than targeting the immune system, Quantum BioPharma’s Lucid-MS targets the myelin sheath. The case for Lucid-MS is grounded in more than a decade of rigorous science. Quantum BioPharma’s path to phase 2 has been methodical and deliberate. To read the Full Publication, visit https://ibn.fm/wILk2 For further information about Quantum BioPharma Ltd., visit the Quantum BioPharma profile. To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com

    21 min

  3. Jun 26

    Next-Generation DNA Repair Therapies Open New Frontiers in Oncology

    BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an estimated $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and precision medicine markets are projected to climb to roughly $750 billion by 2030. New inhibitor classes are emerging as the next major wave. Sitting at the forefront of this shift is Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF), (Profile) a Canadian clinical-stage oncology company developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor that targets a DNA repair enzyme involved in multiple DNA repair pathways. As the field races to find the next generation of synthetic lethality assets, Onco-Innovations occupies a unique space as it strengthens its position in the biopharmaceutical and biotechnology sector, along with other leading companies, such as AstraZeneca plc (NYSE: AZN), Aprea Therapeutics Inc. (NASDAQ: APRE), Boundless Bio Inc. (NASDAQ: BOLD) and Foghorn Therapeutics Inc. (NASDAQ: FHTX), that are focused on developing therapies for serious diseases, particularly cancer. PARP inhibitors transformed oncology when they arrived in the clinic more than a decade ago, but they are only one entry point into a complex biological system. Onco-Innovations holds exclusive global rights to a foundational portfolio of PNKP inhibitor technology. The company’s preclinical program has produced specific, measurable results that support the biological rationale for PNKP inhibition in solid tumors. ONCO holds exclusive global rights across three distinct layers of protection, each reinforcing the others. To read the Full Publication, visit https://ibn.fm/Lhc3W For further information about Onco-Innovations, visit the Onco-Innovations profile.   To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com

    21 min

  4. Jun 26 ·  Video

    Next-Generation DNA Repair Therapies Open New Frontiers in Oncology [Video Edition]

    BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an estimated $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and precision medicine markets are projected to climb to roughly $750 billion by 2030. New inhibitor classes are emerging as the next major wave. Sitting at the forefront of this shift is Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF), (Profile) a Canadian clinical-stage oncology company developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor that targets a DNA repair enzyme involved in multiple DNA repair pathways. As the field races to find the next generation of synthetic lethality assets, Onco-Innovations occupies a unique space as it strengthens its position in the biopharmaceutical and biotechnology sector, along with other leading companies, such as AstraZeneca plc (NYSE: AZN), Aprea Therapeutics Inc. (NASDAQ: APRE), Boundless Bio Inc. (NASDAQ: BOLD) and Foghorn Therapeutics Inc. (NASDAQ: FHTX), that are focused on developing therapies for serious diseases, particularly cancer. PARP inhibitors transformed oncology when they arrived in the clinic more than a decade ago, but they are only one entry point into a complex biological system. Onco-Innovations holds exclusive global rights to a foundational portfolio of PNKP inhibitor technology. The company’s preclinical program has produced specific, measurable results that support the biological rationale for PNKP inhibition in solid tumors. ONCO holds exclusive global rights across three distinct layers of protection, each reinforcing the others. To read the Full Publication, visit https://ibn.fm/Lhc3W For further information about Onco-Innovations, visit the Onco-Innovations profile.   To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com

    21 min

  5. Jun 5

    How Advanced Drug Delivery Could Improve Existing Cancer Treatments

    BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are placing renewed emphasis on improving existing therapeutics through advanced delivery technologies rather than relying exclusively on discovering entirely new drugs. Across the healthcare sector, growing attention is being directed toward nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic strategies designed to potentially improve bioavailability, systemic exposure, tolerability and dosing consistency of established cancer therapies. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) is advancing its Sapu003 program and Deciparticle(TM) platform as part of a larger industry trend focused on scalable nanotechnology-enabled drug delivery and AI-enhanced biomedical infrastructure. The company’s strategy centers on leveraging platform technologies that may support multiple therapeutic applications across oncology and rare disease markets rather than relying solely on a single drug candidate. Oncotelic is one of several companies, including Northwest Biotherapeutics Inc. (OTCQB: NWBO),  Sangamo Therapeutics Inc. (OTCQB: SGMO), HIVE Digital Technologies Ltd. (NASDAQ: HIVE) and Iovance Biotherapeutics Inc. (NASDAQ: IOVA), that are building scalable platforms — whether cancer immunotherapy, genomic medicine, AI/data infrastructure or cell therapy — rather than single-product biotechnology stories alone. Biotechnology companies are increasingly exploring alternative strategies focused on improving the performance of already-approved therapeutics. Oncotelic Therapeutics is advancing delivery-focused technologies intended to potentially improve exposure consistency and therapeutic performance. Nanotechnology-enabled drug delivery has emerged as one of the fastest-growing segments within oncology therapeutics. Oncotelic Therapeutics is pursuing an integrated platform strategy through both Deciparticle and PDAOAI, the company’s AI-enhanced biomedical infrastructure initiative. Investor attention across biotechnology is increasingly shifting toward companies developing differentiated platform technologies capable of supporting multiple drugs and therapeutic indications. To read the full publication, visit: https://ibn.fm/KV2Tw For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile. To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com

    21 min

  6. Jun 5 ·  Video

    How Advanced Drug Delivery Could Improve Existing Cancer Treatments [Video Edition]

    BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are placing renewed emphasis on improving existing therapeutics through advanced delivery technologies rather than relying exclusively on discovering entirely new drugs. Across the healthcare sector, growing attention is being directed toward nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic strategies designed to potentially improve bioavailability, systemic exposure, tolerability and dosing consistency of established cancer therapies. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) is advancing its Sapu003 program and Deciparticle(TM) platform as part of a larger industry trend focused on scalable nanotechnology-enabled drug delivery and AI-enhanced biomedical infrastructure. The company’s strategy centers on leveraging platform technologies that may support multiple therapeutic applications across oncology and rare disease markets rather than relying solely on a single drug candidate. Oncotelic is one of several companies, including Northwest Biotherapeutics Inc. (OTCQB: NWBO),  Sangamo Therapeutics Inc. (OTCQB: SGMO), HIVE Digital Technologies Ltd. (NASDAQ: HIVE) and Iovance Biotherapeutics Inc. (NASDAQ: IOVA), that are building scalable platforms — whether cancer immunotherapy, genomic medicine, AI/data infrastructure or cell therapy — rather than single-product biotechnology stories alone. Biotechnology companies are increasingly exploring alternative strategies focused on improving the performance of already-approved therapeutics. Oncotelic Therapeutics is advancing delivery-focused technologies intended to potentially improve exposure consistency and therapeutic performance. Nanotechnology-enabled drug delivery has emerged as one of the fastest-growing segments within oncology therapeutics. Oncotelic Therapeutics is pursuing an integrated platform strategy through both Deciparticle and PDAOAI, the company’s AI-enhanced biomedical infrastructure initiative. Investor attention across biotechnology is increasingly shifting toward companies developing differentiated platform technologies capable of supporting multiple drugs and therapeutic indications. To read the full publication, visit: https://ibn.fm/KV2Tw For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile. To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com

    21 min

  7. Jun 2

    BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM)

    Disseminated on behalf of Quantum BioPharma, may include paid advertisements. AUSTIN, Texas, June 2, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies. To begin the interview, Durkacz outlined Quantum BioPharma’s primary focus on advancing its lead multiple sclerosis drug candidate, Lucid-MS. “Quantum BioPharma is focused on a drug candidate that is trying to address an issue that exists today for people that suffer from multiple sclerosis,” he said. “If you know anybody that has the disease, you will see that over time there is a progression where they begin to lose control of parts of their body or sometimes their entire body. What our main drug candidate focus, Lucid-MS, is trying to do is reverse that damage that’s been done to people’s mobility. We believe that is something that is not addressed in any drug or therapy today in the world. There are almost three million people that suffer from this debilitating disease.” Join IBN’s Stuart Smith for a conversation with Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma, as he discusses the company’s Lucid-MS development program, its unbuzzd™ commercial strategy and the milestones ahead for 2026. To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 20 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

    17 min

  8. Jun 2 ·  Video

    BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) [Video Edition]

    Disseminated on behalf of Quantum BioPharma, may include paid advertisements. AUSTIN, Texas, June 2, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies. To begin the interview, Durkacz outlined Quantum BioPharma’s primary focus on advancing its lead multiple sclerosis drug candidate, Lucid-MS. “Quantum BioPharma is focused on a drug candidate that is trying to address an issue that exists today for people that suffer from multiple sclerosis,” he said. “If you know anybody that has the disease, you will see that over time there is a progression where they begin to lose control of parts of their body or sometimes their entire body. What our main drug candidate focus, Lucid-MS, is trying to do is reverse that damage that’s been done to people’s mobility. We believe that is something that is not addressed in any drug or therapy today in the world. There are almost three million people that suffer from this debilitating disease.” Join IBN’s Stuart Smith for a conversation with Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma, as he discusses the company’s Lucid-MS development program, its unbuzzd™ commercial strategy and the milestones ahead for 2026. To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 20 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

    17 min
See All (127)

About

Fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation

Information

  • Creator
    podcast@investorbrandnetwork.com
  • Years Active
    2020 - 2026
  • Episodes
    127
  • Rating
    Clean
  • Copyright
    © Copyright 2024. All rights reserved. Disclaimers
  • Show Website
    The BioMedWire Podcast